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High systolic blood pressure (SBP) remains 
the major cause of premature death glob-
ally despite advances in pharmacological 
treatment.1 2 The global direct medical 
costs associated with hypertension treat-
ment are estimated at $370 billion/year 
worldwide, with the healthcare savings 
from effective management of this condi-
tion projected at about $100 billion/year.3 
Unfortunately, relatively little attention 
is given to non- pharmacological strate-
gies, including structured exercise inter-
ventions. A recent network meta- analysis 
of randomised controlled trials (RCTs) 
published in the BJSM4 aimed to compare 
the effects of exercise interventions and 
medications on SBP. We highlight the key 
findings of this network meta- analysis that 
are particularly relevant for clinical prac-
tice and health policy.
The study included 391 RCTs (39,742 
participants), of which 197 (10 461 partic-
ipants) evaluated exercise interventions 
(endurance, resistance, isometric exercise 
or a combination of endurance and resis-
tance) and 194 (29 281 participants) eval-
uated antihypertensive medications. When 
the results from trials that included hyper-
tensive populations (SBP > 140 mm Hg) 
were combined with those from trials that 
included populations with normal levels 
of SBP, all types of antihypertensive drugs, 
and also all exercise modalities or inten-
sities were effective in lowering baseline 
SBP compared with control interventions 
(ie, no exercise and no drugs) (figure 1). 
Antihypertensive medications resulted in 
overall larger reductions in baseline SBP 
compared with exercise. When analysing 
hypertensive individuals (SBP > 140 mm 
Hg) separately, both exercise and antihy-
pertensive medications appeared simi-
larly effective in reducing baseline SBP. 
However, the results and their clinical 
implications should be interpreted with 
Figure 1 Infographic.
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caution, as none of the included studies 
directly compared antihypertensive medi-
cations vs exercise, exercise interventions 
were often evaluated in trials too small 
to adequately control for confounding 
and produce reliable effect estimates and 
populations were healthier than those in 
medication trials.
Further research is therefore needed to 
directly compare the blood pressure (BP) 
lowering effects of exercise and drug inter-
ventions. Recently published guidelines 
from the American College of Cardiology/
American Heart Association5 lowered the 
threshold to define hypertension in adults 
to 130 mm Hg (instead of 140 mm Hg). 
The recently updated European Society of 
Cardiology/European Society of Hyper-
tension guidelines6 define SBP 130139 as 
high normal. Many individuals who were 
previously not indicated for drug therapy 
are thus recommended to start medica-
tions to lower their BP. Whether exercise 
interventions can be considered as viable 
substitutes of antihypertensive medication 
for newly diagnosed hypertensive individ-
uals needs careful evaluation. We also need 
more data to understand the combined 
effects of medications and exercise and 
whether exercise may allow reducing the 
number of antihypertensive agents used 
in patients treated with combinations of 
multiple drugs.
More research is also needed to deter-
mine the effects of exercise to prevent the 
risk (or as a coadjuvant treatment) of some 
hypertension phenotypes that are associ-
ated to a particularly high cardiovascular 
risk despite the use of drug combinations, 
such as resistant hypertension (a condition 
found in subjects receiving three drugs 
of different classes at maximally toler-
ated doses) and a more recently identi-
fied phenotype, the so- called masked 
uncontrolled hypertension, a condition 
found in some patients treated for hyper-
tension with seemingly well- controlled 
BP in the office (or clinic) yet with high 
ambulatory BP.7
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